Abstract:

INTRODUCTION: We showed the clinical implications of the Ki-67 labeling index (LI) in hormone receptor (HR)-positive, HER2-negative (HER2-) breast cancer patients with lower risk (luminal A [LA]-like) and higher risk (luminal B [LB]-like) subtypes.
PATIENTS AND METHODS: Three hundred sixty-nine patients with HR+, HER2- cancers were eligible and we dichotomized these patients into LA-like and LB-like according to Ki-67 LI (14% cutoff) and analyzed prognostic significance of progesterone receptor (PR) expression.
RESULTS: Of 205 LA-like and 163 LB-like subtypes, PR was positive in 149 (73%) and 103 (63%). PR expression was a prognostic factor in the LA-like subtype but not in the LB-like subtype. In LA/PR+, LA/PR-, and LB-like subtypes, the 12-year disease-free survival (DFS) rates were 94.8%, 81.6%, and 79.7% (P = .03), and breast cancer-specific survival (BCSS) rates were 98.4%, 97.4%, and 92.0%, respectively (P = .05). Late recurrence occurred in LA/PR- subtype, and differences in prognosis between LA/PR+ and LA/PR- subtypes emerged >5 years after surgery. Twelve-year DFS rates of the LA/PR- subtype were almost equal to those of the LB-like subtype, whereas 12-year BCSS of the LA/PR- subtype was superior to that of the LB-like subtype. In multivariate analysis, PR expression and tumor size were significant or nearly significant prognostic factors.
CONCLUSION: PR expression and tumor size were independent prognostic factors in the LA-like subtype, and the LA/PR- subtype had the higher risk of recurrence, especially late recurrence, than the LA/PR+ subtype. In LA-like breast cancers, stratification of prognosis according to PR expression and tumor size is important.

日本語要旨: